Matt Duvernay

Matt Duvernay has a strong background in research, particularly in the field of platelet biology and pharmacology. Starting in 2009, they worked at Vanderbilt University as a Research Fellow, focusing on human platelet signaling and coordinating a project on platelet activity in Type II Diabetic patients. In 2016, they became a Research Assistant Professor at the university, leading a team in optimizing a protease-activated receptor antagonist and developing structure activity relationships with chemists. Matt also optimized platelet-based assays to measure drug potency and efficacy. In 2019, they joined Vanderbilt University Medical Center as a Research Assistant Professor, conducting clinical studies on the efficacy of tranexamic acid in orthopaedic surgery and contributing to the optimization of a burn-injury murine model. Currently, they are working at Cartesian Therapeutics as the Associate Director of Research, and their responsibilities will transition to Director of Research in February 2023.

Matt Duvernay obtained a Bachelor of Science degree in Cell and Molecular Biology from Tulane University in 2003. Matt then pursued a Doctor of Philosophy (PhD) in Pharmacology at Louisiana State University Health Sciences Center from 2003 to 2008.